Cardiovascular Endocrinology & Metabolism最新文献_第10页

Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women's Health Initiative. 妇女健康倡议中与代谢体重类别相关的社会人口统计学和代谢风险特征。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000194

Amber R Cordola Hsu, Susan L Ames, Bin Xie, Darleen V Peterson, Lorena Garcia, Scott B Going, Nathan D Wong, Hoda Anton-Culver

{"title":"Sociodemographic and metabolic risk characteristics associated with metabolic weight categories in the Women's Health Initiative.","authors":"Amber R Cordola Hsu, Susan L Ames, Bin Xie, Darleen V Peterson, Lorena Garcia, Scott B Going, Nathan D Wong, Hoda Anton-Culver","doi":"10.1097/XCE.0000000000000194","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000194","url":null,"abstract":"To identify sociodemographic and metabolic correlates of weight categories in postmenopausal women.Methods: The Women's Health Initiative enrolled 161 808 postmenopausal women ages 50-79. We included those free of cardiovascular disease (CVD) and with CVD risk factors and biomarkers (n = 19 412). Normal weight was defined as a BMI ≥18.5 and <25 kg/m2 and waist circumference <88 cm and overweight/obesity as a BMI ≥25 kg/m2 or waist circumference ≥88 cm. Metabolically healthy was based on <2 and metabolically unhealthy ≥2 traits: triglycerides ≥150 mg/dl, systolic blood pressure (BP) ≥130 mmHg or diastolic BP ≥85 mmHg or antihypertensives or diuretics, fasting glucose ≥100 mg/dl or diabetes medication, and high-density lipoprotein cholesterol <50 mg/dl. Polytomous multinomial logistic regression with generalized link logit function provided the odds of metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUHNW), metabolically healthy overweight/obese (MHO), and metabolically unhealthy overweight/obese (MUHO) according to demographic and risk factor measures.Results: Among the 19 412 postmenopausal women, 2369 (12.2%) participants had prevalent diabetes. Advanced age was associated with an increased odds of MUHNW as compared with the MHNW after adjusting for covariates [odds ratio (OR) 1.04, P < 0.0001]. Black/African American ethnicity was associated with a decreased odds of MUHNW (OR 0.64, P < 0.0001) and MUHO (OR 0.77, P = 0.0004), while an increased odds for MHO (OR 1.50, P < 0.0001) as compared with White MHNW.Conclusions: Advanced age and ethnicity are important indicators of metabolic weight categories among postmenopausal women.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000194","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics. 减少充血性心力衰竭再入院率的新策略:间歇性经验性静脉利尿剂。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000200

Ertan Yetkin, Bilal Cuglan, Hasan Turhan, Selcuk Ozturk

{"title":"A novel strategy to reduce the readmission rates in congestive heart failure: intermittent empirical intravenous diuretics.","authors":"Ertan Yetkin, Bilal Cuglan, Hasan Turhan, Selcuk Ozturk","doi":"10.1097/XCE.0000000000000200","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000200","url":null,"abstract":"Improvements in the medical management of heart failure have changed the course of the disease. However, mortality rates, hospitalization rates, and treatment costs are not at desired levels. Diuretics have been widely used in the treatment of congestion in heart failure patients. The following case reports represent a special patient group treated and followed by cardiology clinic. Treatment approach of each case report has been tailored on an individual basis depending on the clinical course and hospitalization rates of patients. Authors have highlighted and discussed the common aspects and future perspectives of their cases in which post-discharge intermittent empirical intravenous diuretic administration dramatically improved the clinical status and readmission number due to decompensated congestive heart failure. This is a relatively new and promising approach, which has been thought to cease the recycle of diuretic resistance and silent increase of fluid congestion in patients with congestive heart failure and frequent hospitalization.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000200","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38043445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA. 针对美国初级保健医生的心血管指南相关建议的重点回顾。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-15 eCollection Date: 2020-06-01 DOI: 10.1097/XCE.0000000000000192

Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton

{"title":"A focused review of cardiovascular guideline related recommendations for the primary care physician in the USA.","authors":"Omar Sheikh, Mouhamed Nashawi, Ayman Battisha, Robert Chilton","doi":"10.1097/XCE.0000000000000192","DOIUrl":"10.1097/XCE.0000000000000192","url":null,"abstract":"Primary care physicians in the USA serve the critical role of first contact for undiagnosed or mismanaged pathologies as well as providers of continuous care in multiple communities. Their scope of practice is broad from medication reconciliation to coordinating specialty care and even performing office procedures. Primary care physicians in the USA commonly encounter patients with diabetes and associated comorbidities related to prolonged insulin resistance. Mainly these include heart failure exacerbation or major adverse cardiovascular events. The demanding roles primary care physicians serve may render these providers encumbered to navigate through long, verbose and dynamic guidelines related to managing diabetes and cardiac diabetology sequelae. Our aim is to compose current, prominent evidence-based points from American medical societies such as the American College of Cardiology/American Heart Association and the American Diabetes Association central to lifestyle modifications, antiplatelet therapy, anti-hyperglycemic and SGLT2-inhibitor utilization, hypertension, dyslipidemia, and heart failure screening in a way that is both succinct and valuable to primary care physicians.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228774/pdf/xce-9-36.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38044010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model. 新型非他汀疗法对心血管糖尿病的系统性影响：以 PCSK9 为例

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-05-05 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000204

Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton

{"title":"The systemic implication of novel non-statin therapies in cardiovascular diabetology: PCSK9 as a case model.","authors":"Mouhamed Nashawi, Omar Sheikh, Mahnoor Mir, Tri Te, Robert Chilton","doi":"10.1097/XCE.0000000000000204","DOIUrl":"10.1097/XCE.0000000000000204","url":null,"abstract":"PCSK9, like other novel non-statin drugs were primarily developed to help patients achieve low-density lipoprotein cholesterol targets, especially in patients with dyslipidemia not achieving lipid goals with statins due to poor tolerance or inadequate response. PCSK9 inhibitors, in addition to modulating lipid metabolism, improve mortality outcomes in cardiovascular disease. These benefits are markedly pronounced in patients with type 2 diabetes mellitus. However, these benefits do not come without associated risk. Multiple trials, studies, and case reports have attempted to explain observed outcomes with PCSK9 expression and administration of PCSK9 inhibitors from multiple perspectives, such as their effects on insulin sensitivity and glucose tolerance, changes in renal physiology, thyroid physiology, vascular tone, intestinal regulation of lipids, and improved cardiovascular function. These agents represent an opportunity for physicians to exercise prudence by using appropriate clinical judgement when managing comorbidities in the hyperglycemic patient, a concept that extends to other novel non-statin drugs.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2020-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673769/pdf/xce-9-143.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38641602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications. COVID-19 心血管并发症发病机制中可能存在的分子和旁分泌作用。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-04-20 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000207

Antoine Fakhry AbdelMassih, David Ramzy, Lauren Nathan, Silvia Aziz, Mirette Ashraf, Nourhan Hatem Youssef, Nouran Hafez, Rana Saeed, Hala Agha

{"title":"Possible molecular and paracrine involvement underlying the pathogenesis of COVID-19 cardiovascular complications.","authors":"Antoine Fakhry AbdelMassih, David Ramzy, Lauren Nathan, Silvia Aziz, Mirette Ashraf, Nourhan Hatem Youssef, Nouran Hafez, Rana Saeed, Hala Agha","doi":"10.1097/XCE.0000000000000207","DOIUrl":"10.1097/XCE.0000000000000207","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) has been declared a pandemic on 11 March 2020 by the WHO. Despite being mainly a respiratory virus, cardiac complications have been described. These range from sudden cardiac death to subtle diastolic dysfunction after recovery from COVID-19. The commonest cardiac presentation to date is acute heart failure resulting from biventricular or left ventricular hypokinesis and elevation of cardiac troponins. It has been shown that COVID-19 downregulates angiotensin-converting enzyme-2, which has protective effects on the endothelium and cardiomyocytes. It has also been proven that COVID-19 induces a state of hypercytokinaemia, some cytokines such as interleukin-1 and interleukin-6 have an injurious effect on the myocardium and endothelium, respectively. Such pathogenic mechanisms might play a crucial role in induction of cardiomyocyte injury and impaired myocardial perfusion probably through coronary endothelial dysfunction. The understanding and linking of such mechanisms might help in tailoring drug repurposing for treatment or prophylaxis of COVID-19 cardiovascular complications.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410028/pdf/xce-9-121.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A 78-year-old male with inferior ST-segment elevation on electrocardiogram, diabetic ketoacidosis and acute pancreatitis. 78岁男性，心电图下st段抬高，糖尿病酮症酸中毒，急性胰腺炎。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-04-17 eCollection Date: 2020-12-01 DOI: 10.1097/XCE.0000000000000205

Jamie S Y Ho, Bryan Mui, Ching-Hui Sia, Andie H Djohan, Shao-Feng Mok, Mark Y Chan, Anand A Ambhore

引用次数: 1

Prevention and management of cardiovascular disease in patients with diabetes: current challenges and opportunities. 糖尿病患者心血管疾病的预防和管理：当前的挑战和机遇。

IF 1.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-04-17 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000199

Dennis Bruemmer, Steven E Nissen

引用次数: 0

Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists. 非酒精性脂肪肝：对内分泌专家和心脏病专家的影响。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-03-23 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000197

Gerardo Rodriguez-Araujo

{"title":"Nonalcoholic fatty liver disease: implications for endocrinologists and cardiologists.","authors":"Gerardo Rodriguez-Araujo","doi":"10.1097/XCE.0000000000000197","DOIUrl":"10.1097/XCE.0000000000000197","url":null,"abstract":"Type 2 diabetes mellitus is not just a risk factor but a progression factor for a plethora of multi-organ complications, including the liver and the vascular system. The profibrogenic-inflammatory liver disease nonalcoholic steatohepatitis affects patient's mortality and overall cardiovascular and liver-related complications. There is an evident overlap between these diseases; therefore, there are important implications for endocrinologists, cardiologists, and hepatologists when treating these patients. In addition, as newly approved nonalcoholic steatohepatitis pharmacotherapy is expected to be available early this year, clinicians need to be able to identify patients with type 2 diabetes mellitus that are at risk of advanced liver fibrosis to establish adequate and efficient management plans to limit or avoid cardiovascular or liver-related complications. In this review, we summarize the current knowledge in the nonalcoholic steatohepatitis field with potential value for clinicians focusing on the implications of the overlap between type 2 diabetes mellitus, cardiovascular disease, and nonalcoholic steatohepatitis, the available diagnostic tools for risk stratification, management pathways, and nonalcoholic steatohepatitis pharmacotherapy, including antidiabetic and cardiovascular drugs that may be beneficial or detrimental to their patients.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7410017/pdf/xce-9-096.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38271993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiometabolic disease in the older person: prediction and prevention for the generalist physician. 老年人心脏代谢疾病:全科医生的预测和预防。

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-02-22 eCollection Date: 2020-09-01 DOI: 10.1097/XCE.0000000000000193

Alan J Sinclair, Ahmed H Abdelhafiz

引用次数: 16

Effects of aerobic and anaerobic exercise on glucose tolerance in patients with coronary heart disease and type 2 diabetes mellitus. 有氧和无氧运动对冠心病和2型糖尿病患者糖耐量的影响

IF 2.3

Cardiovascular Endocrinology & Metabolism Pub Date : 2020-02-21 eCollection Date: 2020-03-01 DOI: 10.1097/XCE.0000000000000188

Bernhard Schwaab, Friderike Kafsack, Edith Markmann, Morten Schütt

{"title":"Effects of aerobic and anaerobic exercise on glucose tolerance in patients with coronary heart disease and type 2 diabetes mellitus.","authors":"Bernhard Schwaab, Friderike Kafsack, Edith Markmann, Morten Schütt","doi":"10.1097/XCE.0000000000000188","DOIUrl":"https://doi.org/10.1097/XCE.0000000000000188","url":null,"abstract":"In patients with coronary heart disease (CHD) and type 2 diabetes mellitus (T2DM), physical activity is strongly advised as nonpharmacological therapy. In general, a moderate aerobic exercise intensity is recommended. It was also proposed, however, that greater intensities tend to yield even greater benefits in HbA1c. Hence, the most appropriate exercise intensity seems not to be established yet. We compared the effect of moderate (aerobic) and vigorous (anaerobic) activity on postprandial plasma glucose.Methods: In 10 consecutive patients (63 ± 12 years, BMI 28.3 ± 2.6 kg/m2, fasting plasma glucose 6.1 ± 1.2 mmol/l), 2-hour plasma glucose was ≥11.1 mmol/l in the oral glucose tolerance test at rest (OGTT-0). Cardiopulmonary exercise test (CPX) was performed until a respiratory exchange ratio (RER) ≥1.20, beeing anaerobic (CPX-1), followed by OGTT-1. A steady-state CPX of 30-minute duration was performed targeting an RER between 0.90 and 0.95, being aerobic (CPX-2), followed by OGTT-2.Results: In CPX-1, maximum exercise intensity (maxIntensity) averaged at 99 ± 30 Watt and peak oxygen consumption (VO2peak) reached 15.9 ± 2.8 ml/min/kg. In CPX-2, aerobic intensity averaged at 29 ± 9 Watt, representing 31% of maxIntensity and 61% of VO2peak. After aerobic exercise, 2-hour plasma glucose was significantly reduced to an average of 9.4 ± 2.3 mmol/l (P < 0.05). Anaerobic exercise did not reduce 2-hour plasma glucose as compared to OGTT-0 (12.6 ± 2.2 vs 12.6 ± 3.9 mmol/l).Conclusion: Aerobic exercise intensity was very low in our patients with CHD and T2DM. Postprandial plasma glucose was reduced only by aerobic exercise. Larger studies on the optimal exercise intensity are needed in this patient cohort.","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":2.3,"publicationDate":"2020-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/XCE.0000000000000188","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37682571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 11